Stock report · Delisted · Nasdaq
Achilles Therapeutics PLC ADR (ACHL)
1.48USD Delisted Final close · Mar 20, 2025
ACHL no longer trades. Achilles Therapeutics PLC ADR was delisted from the Nasdaq in March 2025.
All prices on this page are historical. The last trade was on March 20, 2025, at $1.48.
ACHL stock price history
Final trading statistics
- Final close
- $1.48
- Final trading day
- Mar 20, 2025
- Market cap at delisting
- $60.83M
- Shares outstanding
- 41.10M
- Final 52-week range
- $0.63 – $1.51
- Avg. volume (final 3 mo.)
- 1,272,406
- All-time high
- $17.86 · Apr 2021
- All-time low
- $0.70 · Sep 2024
- Return since IPO
- -91.1%
- Beta
- 1.25
- Book value / share
- $2.51
- Price / book
- 0.59
About Achilles Therapeutics PLC ADR
Achilles Therapeutics was a biopharmaceutical company developing precision T cell therapies for solid tumors. Its platform found mutations that arise early in a cancer's development, and its PELEUS AI-based bioinformatics platform identified clonal neoantigens in each patient.
Its candidates were CHIRON, in a Phase I/IIa trial for advanced non-small cell lung cancer, and THETIS, in a Phase I/IIa trial for metastatic or recurrent melanoma. Formerly Achilles TX Limited, it became Achilles Therapeutics Plc in February 2021.
The company was founded in 2016 and based in London. Its ADRs were delisted from the Nasdaq in March 2025, with the final trade on March 20, 2025 at $1.48.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London
- Employees
- 204
- IPO date
- March 31, 2021
- Delisted
- March 20, 2025
- SEC CIK
- 1830749
Achilles Therapeutics PLC ADR financials before the delisting
The last 5 fiscal years Achilles Therapeutics PLC ADR reported as a public company, fiscal year ending December.
ACHL revenue and net income
ACHL earnings per share
ACHL annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | −$69.7M | −$1.74 |
| FY2022 | $0.00 | −$71.2M | −$1.82 |
| FY2021 | $0.00 | −$61.1M | −$9.62 |
| FY2020 | $0.00 | −$33.2M | −$4.70 |
| FY2019 | $0.00 | −$14.0M | −$5.71 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Achilles Therapeutics PLC ADR stock FAQ
What happened to Achilles Therapeutics PLC ADR stock?
Achilles Therapeutics PLC ADR was delisted from the Nasdaq in March 2025. The final close was $1.48 on March 20, 2025.
Can I still buy ACHL stock?
No. ACHL is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on March 20, 2025.
What was the last price of ACHL?
ACHL last closed at $1.48 on March 20, 2025, which valued the company at about $60.83M.
How did Achilles Therapeutics PLC ADR do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Achilles Therapeutics PLC ADR reported revenue of $0.00 and net income of −$69.7M.
When did Achilles Therapeutics PLC ADR go public?
Achilles Therapeutics PLC ADR shares started trading on March 31, 2021.
ACHL no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.